Form 4: Core Scientific Exec Sells Shares Under 10b5-1 Plan

Core Scientific, Inc. reports that executive Todd DuChene sold a total of 10,000 shares of common stock under a pre-arranged trading plan.

Summary

• Todd DuChene, Chief Legal and Administrative Officer of Core Scientific, Inc., executed a series of stock sales on June 1, 2026.
• These transactions were conducted under a Rule 10b5-1 trading plan adopted on December 5, 2025.
• A total of 10,000 shares of common stock were sold across three reported transactions.
• The sales occurred at weighted average prices ranging from $26.54 to $28.97 per share.
• Following these transactions, DuChene beneficially owns 2,078,895 shares of common stock.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this filing as slightly negative due to the executive stock sales, despite being conducted under a pre-arranged plan. The volume of shares sold and the weighted average prices could signal potential concerns or a desire for personal liquidity.

Negatives

• An executive sold a significant number of shares (10,000 shares) which could be perceived negatively by the market.

Risks

• The sales were executed under a Rule 10b5-1 trading plan, which is designed to mitigate insider trading concerns, but the volume of sales could still impact market perception.
• The weighted average prices indicate a downward trend in the sale prices across the reported transactions.

Future Outlook

The filing does not contain forward-looking statements or guidance. It reports on past transactions.

Management Comments

• The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 5, 2025.
• The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.54 to $27.52, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.
• The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.57 to $28.56, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.
• The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.58 to $28.97, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.

Industry Context

StockSavvy.ai notes that executive stock sales, even under a 10b5-1 plan, can sometimes be interpreted by the market as a lack of confidence in future stock performance, particularly if the sales are substantial relative to the executive's holdings or if they occur during periods of market volatility.

Stakeholder Impact

• Shareholders may view the executive's stock sales with concern, potentially leading to short-term negative sentiment towards the stock.
• Employees with stock options or grants may be affected by any perceived negative market reaction to the sales.

Key Dates

Recommendation

While the sales are under a 10b5-1 plan, the volume and the weighted average prices suggest a cautious approach. A 'hold' recommendation is appropriate pending further company performance updates, as the sales themselves do not provide a clear signal of fundamental change but could influence short-term trading.

Keywords

Core Scientific, CORZ, Form 4, Insider Trading, Stock Sale, Rule 10b5-1, Todd DuChene, Executive Compensation, Beneficial Ownership